The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis

Ungar, Benjamin; Lavin, Leore; Golant, Alexandra; Gontzes, Alyssa; David, Eden; Estrada, Yeriel; Singer, Giselle; Pavel, Ana B.; Guttman‐Yassky, Emma

doi:10.1016/j.anai.2022.03.019

Cited by 12 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 176 Dupilumab (anti‐IL‐4/13 Rα) used in atopic dermatitis (AD) patients with COVID‐19 was associated with a lower IgG antibodies response. 177 Poor and delayed anti‐SARS‐CoV‐2 IgM and IgG antibodies responses correlated with poor outcomes of COVID‐19 in children. 178 A visible antibody cross‐reactivity was reported in infectious bronchitis virus, a non‐SARS‐CoV‐2 infection and chicken aerosol vaccines particularly in highly exposed veterinarians who administered the vaccines.…”

Section: Immune Responses and Pathogenesis Of Covid‐19mentioning

confidence: 99%

“…No deaths were reported in patients with higher an IgG antibody index (NT50/IgG >100) 176 . Dupilumab (anti‐IL‐4/13 Rα) used in atopic dermatitis (AD) patients with COVID‐19 was associated with a lower IgG antibodies response 177 . Poor and delayed anti‐SARS‐CoV‐2 IgM and IgG antibodies responses correlated with poor outcomes of COVID‐19 in children 178 .…”

Section: Immune Responses and Pathogenesis Of Covid‐19mentioning

confidence: 99%

See 1 more Smart Citation

Recent developments in the immunopathology of COVID‐19

Zhang

Sun

Wang

et al. 2022

Allergy

View full text Add to dashboard Cite

There has been an important change in the clinical characteristics and immune profile of Coronavirus disease 2019 patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID-19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID-19. The efficacy of the COVID-19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4, and BA.5 and the global administration of COVID-19 vaccines have changed the clinical scenario of COVID-19. Multisystem inflammatory syndrome in children (MIS-C) may cause severe and heterogeneous disease but with a lower mortality rate. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long-term symptoms of COVID-19. There is conflicting evidence about whether atopic diseases, such as allergic asthma and rhinitis, are associated with a lower susceptibility and better outcomes of COVID-19. At the beginning of pandemic, the European Academy of Allergy and Clinical Immunology (EAACI) developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID-19 vaccines and emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID-19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID-19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID-19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS-CoV-2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high-risk groups, the development of MIS-C and long COVID-19.

show abstract

Section: Immune Responses and Pathogenesis Of Covid‐19mentioning

confidence: 99%

Section: Immune Responses and Pathogenesis Of Covid‐19mentioning

confidence: 99%

Recent developments in the immunopathology of COVID‐19

Zhang

Sun

Wang

et al. 2022

Allergy

View full text Add to dashboard Cite

show abstract

“…A multicenter study by Eger et al (2020) revealed that biologic-treated asthmatics were highly vulnerable to COVID-19 infection and had a higher severity than the general population. In contrast, other studies ( Klimek et al, 2020 ; Patruno et al, 2020 ; Bhalla et al, 2021 ; Grieco et al, 2021 ; Tanabe et al, 2021 ; Ungar et al, 2022a ; Ungar et al, 2022b ) reported that dupilumab is a safe agent to use during the COVID-19 pandemic and may reduce the severity of COVID-19 symptoms. However, the role of biological agents on the COVID-19 response is still unclear, so each patient should be carefully assessed, and the patient should be involved in considering the therapy’s benefits and hazards.…”

Section: Discussionmentioning

confidence: 88%

Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Background: Dupilumab is a human monoclonal antibody directed against the alpha subunit of the interleukin-4 receptor and inhibits the signaling of IL-4 and IL-13. It is approved for treating asthma and other type-2 inflammatory diseases. There is a conflict in the literature regarding the safety and efficacy of dupilumab. Thus, we aimed to assess the safety and efficacy of dupilumab in patients with moderate to severe asthma.Methods: Six databases (PubMed, Embase, Scopus, Web of Science, Cochrane library, and clinicaltrials.gov registry) were searched until January 2022. We included randomized controlled trials that compared dupilumab with the placebo in moderate to severe asthma patients. We extracted the data at 12 and 24 weeks and analyzed them using review manager 5.4.Findings: Thirteen trials were included. Dupilumab significantly improved the forced expiratory volume in 1 s, asthma control questionnaire score, the fraction of exhaled nitric oxide level, and immunoglobulin E level at 12 and 24 weeks (p < 0.05). However, it was associated with increased blood eosinophils at 12 and 24 weeks. Dupilumab was generally a safe agent for asthmatic patients. It showed no significant difference compared with the placebo regarding most adverse events.Conclusion: Dupilumab improves pulmonary function and reduces local and systemic inflammatory markers with minimal adverse events in patients with moderate to severe asthma.

show abstract

“…No deaths were reported in patients with higher a IgG antibody index (NT50/IgG> 100) 139 . Dupilumab (anti-IL-4/13 Rα) used in atopic dermatitis (AD) patients with COVID-19 was associated with a lower IgG antibodies response 140 .…”

Section: Organs and Systems Symptomsmentioning

confidence: 99%

Recent developments in the immunopathology of COVID-19

Gao

Zhang

Sun

et al. 2022

Preprint

View full text Add to dashboard Cite

There has been an important change in the clinical characteristics and immune profile of COVID-19 patients during the pandemic thanks to the extensive vaccination programs. Here, we highlight recent studies on COVID-19, from the clinical and immunological characteristics to the protective and risk factors for severity and mortality of COVID-19. The efficacy COVID-19 vaccines and potential allergic reactions after administration are also discussed. The occurrence of new variants of concerns such as Omicron BA.2, BA.4 and BA.5 and the global administration of COVID-19 vaccines have changed the clinical scenario of COVID-19. Multisystem inflammatory syndrome in children (MIS-C) has been identified as an important cause of death of children with COVID-19. Perturbations in immunity of T cells, B cells, and mast cells, as well as autoantibodies and metabolic reprogramming may contribute to the long-term symptoms of COVID-19. Atopic diseases, such as allergic asthma and rhinitis, have been shown to be associated with a lower susceptibility and better outcomes of COVID-19. At the beginning of pandemic, EAACI developed guidelines that provided timely information for the management of allergic diseases and preventive measures to reduce transmission in the allergic clinics. The global distribution of COVID-19 vaccines and emerging SARS-CoV-2 variants with reduced pathogenic potential dramatically decreased the morbidity, severity, and mortality of COVID-19. Nevertheless, breakthrough infection remains a challenge for disease control. Hypersensitivity reactions (HSR) to COVID-19 vaccines are low compared to other vaccines, and these were addressed in EAACI statements that provided indications for the management of allergic reactions, including anaphylaxis to COVID-19 vaccines. We have gained a depth knowledge and experience in the over 2 years since the start of the pandemic, and yet a full eradication of SARS-CoV-2 is not on the horizon. Novel strategies are warranted to prevent severe disease in high-risk groups, the development of MIS-C and long COVID.

show abstract

The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis

Cited by 12 publications

References 5 publications

Recent developments in the immunopathology of COVID‐19

Recent developments in the immunopathology of COVID‐19

Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis

Recent developments in the immunopathology of COVID-19

Contact Info

Product

Resources

About